Ticagrelor vs Clopidogrel for Complex Percutaneous Coronary Intervention in Chronic Coronary Syndrome
Authors' conclusion
In chronic coronary syndrome, patients undergoing a complex PCI have higher rates of periprocedural and cardiovascular events that are not reduced by ticagrelor as compared with clopidogrel.
Study context
- Population
- Chronic coronary syndrome patients undergoing elective percutaneous coronary intervention (PCI)910 complex PCI (48.3%)
- Participants
- 1,866 patients
- Comparison
- Complex PCI vs non-complex PCI; ticagrelor vs clopidogrel
- Complex PCIn = 910
- Primary endpoint
- Composite of type 4a or b myocardial infarction (MI) and major myocardial injury
- Follow-up
- 48 hours after PCI
Methodological detailsblinded PCI review
- Blinded PCI review
Primary result
As reported in the abstract
P < 0.001
- No interaction between PCI complexity and randomized treatment (ticagrelor vs clopidogrel)
- P for interaction = 0.47
Secondary outcomes
Type 4 MI
P < 0.001
Angiographic complications
P < 0.05
Death, MI and stroke · 48 hours
P < 0.05
Death, MI and stroke · 30 days
P < 0.05
Secondary endpoints, interaction with randomized treatment
- No interaction between PCI complexity and randomized treatment
Original publication
Ticagrelor vs Clopidogrel for Complex Percutaneous Coronary Intervention in Chronic Coronary Syndrome. JACC Cardiovasc Interv. Published 12 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →